Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting-Reference-Cited by-同舟云学术

Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting

Published:2011-04 Issue:4 Volume:33 Page:482-497
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Asseburg Christian,Frank Martin,Köhne Claus-Henning,Hartmann Jörg Thomas,Griebsch Ingolf,Mohr Andrea,Osowski Ulrike,Schulten Jeltje,Mittendorf Thomas

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference29 articles.

1. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009

2. Estimates of the cancer incidence and mortality in Europe in 2006;Ferlay;Ann Oncol,2007

3. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival;Adam;Ann Surg,2004

4. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study;Saltz;J Clin Oncol,2008

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran;Cancer Control;2023-04

2. Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia;Value in Health Regional Issues;2022-03

3. Health economic studies of colorectal cancer and the contribution of administrative data: A systematic review;European Journal of Cancer Care;2021-06-21

4. Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review;2020-09-29

5. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan;Clinical Therapeutics;2020-07